Corp Ltd Eight Sells 46,238 Shares of VolitionRX Ltd (NYSEAMERICAN:VNRX) Stock

VolitionRX Ltd (NYSEAMERICAN:VNRX) major shareholder Corp Ltd Eight sold 46,238 shares of VolitionRX stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.03, for a total value of $278,815.14. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of NYSEAMERICAN:VNRX traded down $0.12 during trading on Wednesday, hitting $5.42. 1,900 shares of the stock were exchanged, compared to its average volume of 128,688. VolitionRX Ltd has a 1-year low of $1.67 and a 1-year high of $6.84.

VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Monday, August 12th. The medical research company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.

An institutional investor recently raised its position in VolitionRX stock. Morgan Stanley increased its stake in shares of VolitionRX Ltd (NYSEAMERICAN:VNRX) by 15.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,350 shares of the medical research company’s stock after buying an additional 12,600 shares during the quarter. Morgan Stanley owned 0.25% of VolitionRX worth $296,000 at the end of the most recent reporting period.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Featured Article: Trade War

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with's FREE daily email newsletter.